B. Metzler Seel. Sohn & Co. Ag Biogen Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.53 Billion
- Q4 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Biogen Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 10,128 shares of BIIB stock, worth $1.45 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,128
Previous 7,361
37.59%
Holding current value
$1.45 Million
Previous $1.43 Million
8.56%
% of portfolio
0.02%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding BIIB
# of Institutions
1,007Shares Held
131MCall Options Held
1.77MPut Options Held
2.34M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.4 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.3 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.08 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$1.06 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA4.93MShares$706 Million0.14% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.6B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...